Nucleus RadioPharma Secures $56 Million Series A Funding to Expand Production of Radiopharmaceutical Treatments for Cancer Patients

Co-led by Eclipse and GE HealthCare, the investment will accelerate research, streamline supply chains, and make targeted radiopharmaceutical therapies accessible.

Today, Nucleus RadioPharma, the world’s first fully integrated development, manufacturing, and supply chain organization for radiopharmaceuticals has announced an oversubscribed $56 million Series A funding round led by Eclipse and GE HealthCare with participation from Echo Global, Fox Chase Cancer Center, Granger Management, Mayo Clinic, Mercy Health, and University of Missouri. With this round of funding, Nucleus RadioPharma will establish multiple new manufacturing facilities around the country, including Rochester, Minnesota, near Mayo Clinic, and build novel technology for the development, manufacturing, and distribution of radiopharmaceuticals.

Read more at Business Wire


Related Posts